Background Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-19
antiviral treatments, but their antiviral activities in patients have not been compared …

Brief summary In early symptomatic COVID-19 treatment, high dose oral favipiravir did not
accelerate viral clearance. Background Favipiravir, an anti-influenza drug, has in vitro antiviral …

Background: There is no generally accepted methodology for in vivo assessment of antiviral
activity in SARS-CoV-2 infections. Ivermectin has been recommended widely as a treatment …

Background Uncertainty over the therapeutic benefit of parenteral remdesivir in coronavirus
disease 2019 (COVID-19) has resulted in varying treatment guidelines. Methods In a …

Background Effective antiviral drugs prevent hospitalisation and death from COVID-19.
Antiviral efficacy can be efficiently assessed in vivo by measuring rates of SARS-CoV-2 …

Background Clinical trials in severe falciparum malaria require a large sample size to detect
clinically meaningful differences in mortality. This means few interventions can be evaluated …

Background Uncertainty over the therapeutic benefit provided by parenteral remdesivir in
COVID-19 has resulted in varying treatment guidelines. Early in the pandemic the monoclonal …

Background There is no generally accepted methodology for in vivo assessment of antiviral
activity in SARS-CoV-2 infection. Ivermectin has been recommended widely as a treatment …

Background Melioidosis is a frequently fatal disease caused by an environmental bacterium
Burkholderia pseudomallei. The disease is prevalent in northeast Thailand, particularly …

Background The selective serotonin reuptake inhibitors (SSRIs) fluoxetine and fluvoxamine
were repurposed for the treatment of early COVID-19 based on their antiviral activity in vitro, …